BCL2 and breast cancer: Abdel-Fatah et al. (2013) in the large cohort of 635 patients with early advanced TN breast cancers have found that BCL-2 negativity was associated with approximately twice the risk of death and recurrence in patients who did not receive CT or were treated with CMF.